Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Sarac... by Smilde, BJ, Stockklausner, C, Keen, R, Whittaker, A, Bullock, AN, von Delft, A, van Schoor, NM, Yu, PB, Eekhoff, EMW

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva by Williams, E, Bagarova, J, Kerr, G, Xia, D-D, Place, ES, Dey, D, Shen, Y, Bocobo, GA, Mohedas, AH, Huang, X, Sanderson, PE, Lee, A, Zheng, W, Economides, AN, Smith, JC, Yu, PB, Bullock, AN